BridgeBio has substantially advanced the development of a new treatment for cardiac amyloidosis, leveraging the compound. Early patient data suggests potential outcomes for patients diagnosed by this debilitating https://bridgebio753616.acidblog.net/73422110/bridgebio-progresses-attr-cm-therapy-with-attruby